A case report of spitzoid melanoma immunohistochemically testing the p16 tumoral status revealed the absence of p16, connected to a loss of genomic CDKN2A copy.[19] Compared to the limited and sometimes null diagnostic importance of BRAF or NRAS genetic testing in spitzoid melanomas, CDKN2A genetic alterations should be investigated and have been labeled as beneficial in the subsequent therapeutic and secondary prophylaxis management.[20]. This evidence concerns the gene CDKN2A and melanoma.